Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + zanubrutinib + methotrexate for newly diagnosed primary CNS diffuse large B-cell lymphoma (phase 2, single-arm, China)
ChiCTR2300071346Phase 2Recruiting
- Sponsor
- Shengli Oilfield Central Hospital
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, zanubrutinib and methotrexate in Diffuse Large B-Cell Primary Central Nervous System Lymphoma, sponsored by Shengli Oilfield Central Hospital. Primary endpoint: event free survival. Started May 2023; status: recruiting.
02
Drugs
tislelizumabzanubrutinibmethotrexate
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ChiCTR2300071346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071346.